Biotech

The Vetr crowd downgraded its rating for McKesson Corporation (NYSE: MCK) on Monday from 4 stars (Buy), issued 11 days ago, to 3 stars (Hold). Crowd sentiment at the time of the downgrade was generally positive, with 75 percent of Vetr user ratings bullish. Share price in McKesson spiked nearly 10...

At the end of April, biotech company Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the FDA had accepted the resubmission of its Biologics License Application (BLA) for a drug called Kevzara. The acceptance qualified the application for a Class 1 response and sets the company up for a...

Commenting on Mylan N.V. (NASDAQ: MYL), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. That said, the firm thinks Mylan's chances are better than current market expectations. Analysts...

Following the publication of full data from a late-stage study of La Jolla Pharmaceutical Company (NASDAQ: LJPC)'s LPJC-501, a proprietary formulation of angiotensin II, SunTrust Robinson Humphrey said it expects approval in 2018. The Study And The Results The full data from the Phase III study,...

Morgan Stanley analysts David Lewis and Jonathan Demchick raised their price target on Intuitive Surgical, Inc. (NASDAQ: ISRG) from $840 to $950. The analysts maintain an Overweight rating. Lewis and Demchick highlighted Intuitive posted five straight quarters of company-adjusted procedure...

Shares of Puma Biotechnology Inc (NASDAQ: PBYI) soared higher by more than 70 percent on Monday after the U.S. Food and Drug Administration posted briefing documents ahead of the regulatory body's review of Puma's PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage...

Canaccord Genuity analyst John Newman maintains his Buy rating and price target of $85 on Radius Health Inc (NASDAQ: RDUS). Newman stated, “We continue to believe that RDUS' Tymlos will become an important therapy in the osteoporosis market, increasing shareholder value. We also believe...

Shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC) were trading lower by more than 8 percent Monday morning after the company released Phase 3 results in the New England Journal of Medicine from a study called ATHOS-3, which evaluated the company's therapy LJPC-501 for the treatment of...

Sometimes, efforts that begin with the best intentions can just end up making things worse. The Centers for Disease Control and state and local regulators have been fighting the national epidemic of prescription opioid painkiller abuse by increasing regulation of prescription opioid drugs and...

Leerink initiated coverage of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) with an Outperform rating and a $5 price target. New Management As A Catalyst For Growth Leerink analyst Joseph Schwartz noted several opportunities could create a significant amount of shareholder value, including the...

The cannabis industry is creating rapid wealth among investors. However, few entrepreneurs have been as successful as Andy Williams, co-star of MSNBC's “The Pot Barons of Colorado” and founder and CEO of Medicine Man Denver, Medicine Man Technologies Inc (OTC: MDCL) and several...

The American Society of Clinical Oncology, or ASCO, has scheduled its annual meeting on June 2–6, 2017, at McCormick Place, Chicago. The five-day event has Conquer Cancer Foundation as its lead sponsor. The event, typically attended by over 30,000, will be marked by presentations of...

A spokesperson for Mallinckrodt PLC (NYSE: MNK) rejected on Friday an assertion by short-seller Jim Chanos, who said he was shorting both Mallinckrodt and Express Scripts Holding Company (NASDAQ: ESRX) because their alliance could hurt investors. Chanos slammed Mallinckrodt’s exclusive...

The Vetr crowd on Thursday upgraded its rating for Teva Pharmaceutical Industries Limited (ADR) (NYSE: TEVA) from 3.5 stars (Buy), issued 15 days ago, to 4.5 stars (Strong Buy). Crowd sentiment at the time of the downgrade was mostly bullish, with 81 0percent of Vetr user ratings bullish. Share...

The Vetr crowd upgraded its rating for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from 1 star (Strong Sell), issued three days ago, to 3 stars (Hold). Crowd sentiment at the time of the downgrade was edging cautious, with 55 percent of Vetr user ratings bearish. May has been good to shares in...